130 related articles for article (PubMed ID: 7077535)
1. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
Johnson DK; Pippard MJ; Murphy TB; Rose NJ
J Pharmacol Exp Ther; 1982 May; 221(2):399-403. PubMed ID: 7077535
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
[TBL] [Abstract][Full Text] [Related]
3. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Richardson DR; Ponka P
J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
[TBL] [Abstract][Full Text] [Related]
4. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
Bláha K; Cikrt M; Nerudová J; Ponka HF
Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Baker E; Vitolo ML; Webb J
Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
[TBL] [Abstract][Full Text] [Related]
6. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
7. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
8. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
Cikrt M; Ponka P; Necas E; Neuwirt J
Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture.
Baker E; Richardson D; Gross S; Ponka P
Hepatology; 1992 Mar; 15(3):492-501. PubMed ID: 1544632
[TBL] [Abstract][Full Text] [Related]
10. Effect of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture.
Richardson D; Baker E; Ponka P; Wilairat P; Vitolo ML; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):81-8. PubMed ID: 3390577
[No Abstract] [Full Text] [Related]
11. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
Vitolo ML; Clare BW; Hefter GT; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
[No Abstract] [Full Text] [Related]
12. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
Hershko C; Grady RW; Link G
Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
[TBL] [Abstract][Full Text] [Related]
14. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
15. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes.
Ponka P; Richardson D; Baker E; Schulman HM; Edward JT
Biochim Biophys Acta; 1988 Oct; 967(1):122-9. PubMed ID: 3167093
[TBL] [Abstract][Full Text] [Related]
16. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
17. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the stability of aromatic hydrazones in plasma and related biological material.
Kovaríková P; Mrkvicková Z; Klimes J
J Pharm Biomed Anal; 2008 Jun; 47(2):360-70. PubMed ID: 18294799
[TBL] [Abstract][Full Text] [Related]
19. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
[TBL] [Abstract][Full Text] [Related]
20. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents.
Ponka P; Borová J; Neuwirt J; Fuchs O; Necas E
Biochim Biophys Acta; 1979 Aug; 586(2):278-97. PubMed ID: 476142
[No Abstract] [Full Text] [Related]
[Next] [New Search]